Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment

Inflammation Research

Volumn 61, Issue 9, 2012, Pages 1021-1029

  Schurigt, Uta ^a   Eilenstein, Rene ^a   Gajda, Mieczyslaw ^a   Leipner, Carola ^a   Sevenich, Lisa ^b   Reinheckel, Thomas ^b   Peters, Christoph ^b   Wiederanders, Bernd ^a   Bräuer, Rolf ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antigen induced arthritis; Cathepsin L; Cathepsin V; Rheumatoid arthritis; T helper cells

Indexed keywords

ANTIGEN; CATHEPSIN L; CATHEPSIN V;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME DEFICIENCY; HELPER CELL; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; JOINT DESTRUCTION; JOINT SWELLING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; THYMUS; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CATHEPSIN L; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SERUM ALBUMIN, BOVINE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84865136781     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0495-x     Document Type: Article

References (41)

1. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2(6):473-88. (Pubitemid 37361728)
2. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci. 2004;9:2323-34.
3. Fournier C. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine. 2005;72(6):527-32. (Pubitemid 41821411)
4. Kinne RW, Palombo-Kinne E, Emmrich F. T-cells in the pathogenesis of rheumatoid arthritis Villains or accomplices? Biochim Biophys Acta. 1997;1360(2):109-41. (Pubitemid 27171145)
5. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42. (Pubitemid 46834849)
6. Hou WS, Li W, Keyszer G, Weber E, Levy R, Klein MJ, et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002;46(3): 663-74. (Pubitemid 34214249)
7. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 2001;44(8): 1744-53. (Pubitemid 32758219)
8. Pozgan U, Caglic D, Rozman B, Nagase H, Turk V, Turk B. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem. 2010;391(5):571-9.
9. Mort JS, Recklies AD, Poole AR. Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. Arthritis Rheum. 1984;27(5):509-15. (Pubitemid 14140024)
10. Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ, et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol. 2008;173(1):161-9. (Pubitemid 351947964)
11. Schurigt U, Hummel KM, Petrow PK, Gajda M, Stockigt R, Middel P, et al. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factortransgenic mice. Arthritis Rheum. 2008;58(2):422-34. (Pubitemid 351294877)
12. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem. 2004;279(7):5470-9. (Pubitemid 38220571)
13. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347-52. (Pubitemid 29177183)
14. Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, et al. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol. 2009;613(1-3):155-62.
15. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E, Bromme D. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem. 2004;279(35):36761-70. (Pubitemid 39129024)
16. Nguyen Q, Mort JS, Roughley PJ. Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. Biochem J. 1990;266(2):569-73. (Pubitemid 20090162)
17. Kakegawa H, Nikawa T, Tagami K, Kamioka H, Sumitani K, Kawata T, et al. Participation of cathepsin L on bone resorption. FEBS Lett. 1993;321(2-3):247- 50. (Pubitemid 23114087)
18. Spira D, Stypmann J, Tobin DJ, Petermann I, Mayer C, Hagemann S, et al. Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J Biol Chem. 2007;282(51): 37045-52.
19. Keyszer G, Redlich A, Haupl T, Zacher J, Sparmann M, Engethum U, et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis Rheum. 1998;41(8):1378-87. (Pubitemid 28373116)
20. Biroc SL, Gay S, Hummel K, Magill C, Palmer JT, Spencer DR, et al. Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum. 2001;44(3):703-11. (Pubitemid 32234630)
21. Schedel J, Seemayer CA, Pap T, Neidhart M, Kuchen S, Michel BA, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther. 2004;11(13):1040-7. (Pubitemid 39023108)
22. Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon- Dumenil AM, Riese RJ, et al. Proteases involved in MHC class II antigen presentation. Immunol Rev. 1999;172:109-20. (Pubitemid 30000473)
23. Colbert JD, Matthews SP, Miller G, Watts C. Diverse regulatory roles for lysosomal proteases in the immune response. Eur J Immunol. 2009;39(11):2955-65.
24. Zhang T, Maekawa Y, Sakai T, Nakano Y, Ishii K, Hisaeda H, et al. Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice. Int Immunol. 2001;13(8):975-82. (Pubitemid 32750500)
25. Katunuma N, Matsunaga Y, Himeno K, Hayashi Y. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem. 2003;384(6):883-90. (Pubitemid 36874502)
26. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998;280(5362):450-3. (Pubitemid 28208170)
27. Sevenich L, Hagemann S, Stoeckle C, Tolosa E, Peters C, Reinheckel T. Expression of human cathepsin L or human cathepsin V in mouse thymus mediates positive selection of T helper cells in cathepsin L knock-out mice. Biochimie. 2010;92(11):1674-80.
28. Schurigt U, Stopfel N, Huckel M, Pfirschke C, Wiederanders B, Brauer R. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther. 2005;7(1):R174-88.
29. Irmler IM, Gajda M, Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol. 2007;179(9):6228-36.
30. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 2000;14(13):2075-86.
31. Hagemann S, Gunther T, Dennemarker J, Lohmuller T, Bromme D, Schule R, et al. The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol. 2004;83(11-12):775- 80. (Pubitemid 40123841)
32. Huckel M, Schurigt U, Wagner AH, Stockigt R, Petrow PK, Thoss K, et al. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res Ther. 2006;8(1):R17.
33. Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4?CD25? T cells. Arthritis Res Ther. 2005;7(2):R291-301.
34. Petrow PK, Thoss K, Katenkamp D, Brauer R. Adoptive transfer of susceptibility to antigen-induced arthritis into severe combined immunodeficient (SCID) mice: role of CD4? and CD8? T cells. Immunol Invest. 1996;25(4):341-53. (Pubitemid 26230600)
35. Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW, et al. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol. 2004;135(3):409-15. (Pubitemid 38297140)
36. Reinheckel T, Deussing J, Roth W, Peters C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem. 2001;382(5): 735-41. (Pubitemid 32631710)
37. Maehr R, Mintern JD, Herman AE, Lennon-Dumenil AM, Mathis D, Benoist C, et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest. 2005;115(10): 2934-43. (Pubitemid 41434421)
38. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):560-5.
39. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest. 2003;112(4):517-26. (Pubitemid 38056336)
40. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010;120(10): 3421-31.
41. Viken MK, Sollid HD, Joner G, Dahl-Jorgensen K, Ronningen KS, Undlien DE, et al. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and earlyonset myasthenia gravis. Hum Immunol. 2007;68(9):748-55. (Pubitemid 47379976)